WilliamsDMSreedharSSMickellJJChanJC. Acute kidney failure: a pediatric experience over 20 years. Arch Pediatr Adolesc Med. 2002;156: 893-900.
2.
TarrPIGordonCAChandlerWL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005;365:1073-1086.
3.
NathansonSKwonTElmalehM. Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2010;5:1218-1228.
4.
LoiratCSonsinoEHinglaisNJaisJPLandaisPFermanianJ. Treatment of the childhood haemolytic uraemic syndrome with plasma: a multicentre randomized controlled trial. Pediatr Nephrol. 1988;2:279-285.
5.
ScheiringJRosalesAZimmerhacklLB. Today’s understanding of the haemolytic uraemic syndrome. Eur J Pediatr. 2010;169:7-13.
6.
NorrisMRemuzziG. Atypical hemolytic–uremic syndrome. N Engl J Med. 2009;361:1676-1687.
7.
GitiauxCKrugPGreventD. Brain magnetic resonance imaging pattern and outcome in children with haemolytic-uraemic syndrome and neurological impairment treated with eculizumab. Dev Med Child Neurol. 2013;55:758-765.
8.
LapeyraqueALMalinaMFremeaux-BacchiV. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med. 2011;364:2561-2563.
9.
OrthDKhanABNaimA. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol. 2009;182:6394-6400.
10.
StahlALSartzLKarpmanD. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli–induced hemolytic uremic syndrome. Blood. 2011;117:5503-5513.
11.
MorigiMGalbuseraMGastoldiS. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol. 2011;187:172-180.
12.
GreinacherAFrieseckeSAbelP. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4–associated haemolytic uraemic syndrome: a prospective trial. Lancet. 2011;378:1166-1173.
